Stay updated with breaking news from Pieris Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Severe Asthma Treatment MarketAccording to Future Market Insights, the global Severe Asthma Treatment Market sales will expand at a 5.1% CAGR from 2023 to 2033, reaching US$ 36.18 billion by 2033. Severe Asthma Treatment has undergone a huge shift with the emergence of biologics and customised treatments, offering h...
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4 recepto
During the forecast period 2023 to 2033, the severe asthma treatment market is expected to grow at a value of 5.1% CAGR, according to Future Market Insights. By the year 2033, the global market for severe asthma treatment is expected to rise up to a market valuation of US$ 36.18 Billion. Growth of the market can be...
The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing
/PRNewswire/ -- DelveInsight's Severe Asthma Market Insights report proffers a detailed comprehension of Severe Asthma market size by treatment, epidemiology,...